Coronavirus

EQS-News: DEAG fully on track with very good organic business development in 2023 – Detlef Kornett named sole CEO of DEAG

Retrieved on: 
星期三, 四月 10, 2024
EUR, Tax, Growth, Supervisory board, CFO, Coronavirus, Senior, Spanish, Investment, Depreciation, Artisan Entertainment, Film industry

EUR 31 million

Key Points: 
  • EUR 31 million
    Successful execution of buy-and-build strategy, set to remain integral to future growth
    Detlef Kornett appointed sole CEO effective April 2024 – DEAG founder Prof. Peter L.H.
  • The company's growth trajectory has been marked by sustained high profitability, resembling levels seen in the previous year.
  • DEAG is also reorganising its Executive Board: The company founder and CEO of DEAG, Prof. Peter L.H.
  • Schwenkow, CEO and founder of DEAG: “We are once again very pleased with our development in 2023.

EQS-News: Berentzen-Gruppe Aktiengesellschaft publishes 2023 Annual Report

Retrieved on: 
星期三, 四月 10, 2024
Annual, Tax, General Standard, Consolidated, Growth, Supervisory board, Frankfurt Stock Exchange, Coronavirus, Research, History, Policy, Annual report, Fruit, Depreciation

Revenue and earnings targets met in financial year 2023, forecast for 2024 announced

Key Points: 
  • Revenue and earnings targets met in financial year 2023, forecast for 2024 announced
    Consolidated revenues rise to EUR 185.7 million, consolidated EBIT comes to EUR 7.7 million
    Haselünne, March 28, 2024 – Berentzen-Gruppe Aktiengesellschaft, which is listed on the regulated market (General Standard) of the Frankfurt Stock Exchange (ISIN: DE0005201602), today published its Annual Report for the 2023 financial year.
  • “Despite the multiple crises that have impacted us all in the last few years, the Berentzen Group turned in a solid performance in financial year 2023”, said Oliver Schwegmann, CEO of Berentzen-Gruppe Aktiengesellschaft.
  • The Berentzen Group also announced its forecast for the 2024 financial year in the Annual Report 2023.
  • The 2023 Annual Report is published at: https://www.berentzen-gruppe.de/en/investors/reports

EQS-News: MEDICLIN achieves consolidated Group sales of EUR 730.1 million in 2023 - outlook for 2024 is positive

Retrieved on: 
星期三, 四月 10, 2024
EUR, WKN, CFO, Coronavirus, Sale, Bad, MED, Ticker, Rehabilitation, Lithium

At Group level, sales of EUR 730.1 million were achieved, an increase of 3.6% compared to 2022.

Key Points: 
  • At Group level, sales of EUR 730.1 million were achieved, an increase of 3.6% compared to 2022.
  • At EUR 12.7 million, the Group operating result was EUR 6.8 million below the previous year's figure (2022: EUR 19.5 million) due to a one-off effect.
  • Sales include services from the protective shield totalling EUR 7.4 million, which is less than in 2022 (EUR 11.7 million).
  • Sales in the acute segment totalled EUR 254.0 million, an increase of EUR 1.3 million or 0.5% compared to the previous year.

EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Retrieved on: 
星期三, 四月 10, 2024
Annual, Annual report, Tax, BioNTech, Coronavirus, Inflammation, Acquisition, Management, Dermatology, Depreciation, Pain, Growth, Parallel, Pharmaceutical industry

Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Key Points: 
  • Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
    The issuer is solely responsible for the content of this announcement.
  • » Adjusted consolidated EBITDA margin: 27.3%
    Grünwald, 14 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for financial year 2023.
  • Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) declined by 13.8% to EUR 310.2 million (prior-year period: EUR 359.8 million).
  • We exceeded our guidance for consolidated revenue and reached the upper end of the forecast range for adjusted EBITDA.

EQS-News: Deutsche EuroShop: Operating business picks up in financial year 2023

Retrieved on: 
星期三, 四月 10, 2024
Annual report, Tax, EBT, Deutsch, Growth, Coronavirus, Acquisition, EPRA, Investment, IAS, FFO, Deutsche EuroShop

Hamburg, 19 March 2024 – The shopping center investor Deutsche EuroShop this evening announced its preliminary and as yet unaudited results for financial year 2023.

Key Points: 
  • Hamburg, 19 March 2024 – The shopping center investor Deutsche EuroShop this evening announced its preliminary and as yet unaudited results for financial year 2023.
  • “We recorded significant growth in 2023, both in operational terms and in relation to our investment portfolio.
  • 5.7% more people visited our shopping centers and our tenants increased their retail sales by 8.6% compared to 2022,” explains Executive Board member Hans-Peter Kneip.
  • The portfolio includes the Main-Taunus-Zentrum near Frankfurt, the Altmarkt-Galerie in Dresden and the Galeria Baltycka in Gdansk, among many others.

Jiumaojiu Announces 2023 Annual Results

Retrieved on: 
星期五, 三月 22, 2024
Republic, Growth, Relaxation, Coronavirus, COVID-19, Pandemic, City, Restaurant, Food delivery

HONG KONG, Mar 22, 2024 - (ACN Newswire) - Jiumaojiu International Holdings Limited ("Jiumaojiu" or the "Company" and its subsidiaries (together, the "Group"); Stock Code: 9922HK) is pleased to announce the audited consolidated results of the Company for the year ended December 31, 2023.

Key Points: 
  • HONG KONG, Mar 22, 2024 - (ACN Newswire) - Jiumaojiu International Holdings Limited ("Jiumaojiu" or the "Company" and its subsidiaries (together, the "Group"); Stock Code: 9922HK) is pleased to announce the audited consolidated results of the Company for the year ended December 31, 2023.
  • As of December 31, 2023, the Group had a total of 578 Tai Er restaurants, 62 Song Hot Pot restaurants, 77 Jiumaojiu restaurants, 1 Uncle Chef restaurant, 7 Lai Mei Li Grilled Fish restaurants and 1 Fresh Wood restaurant.
  • In addition, revenue from Song Hot Pot as a percentage of total revenue increased from 6.5% in 2022 to 13.5% in 2023.
  • In 2023, the Group experienced accelerated growth in both its restaurant operations and delivery services revenue.

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Retrieved on: 
星期四, 三月 28, 2024
COCP, MERS, Research, SARS, Enzyme, Drug discovery, Influenza, CFO, COVID-19, Lung, Coronavirus, RNA, Gastroenteritis, G&A, Death, SARS-CoV-2, Trial of the century, IND, Disease, World Health Organization, Post-exposure prophylaxis, Clinical trial, CDC, Safety, Pharmacokinetics, Cocrystal, Therapy, FDA, Pharmaceutical industry

Our drug-discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.

Key Points: 
  • Our drug-discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.
  • Cocrystal reported unrestricted cash as of December 31, 2023 of $26.4 million, compared with $37.1 million as of December 31, 2022.
  • Net cash used in operating activities for 2023 was $14.7 million, compared with $21.4 million for 2022.
  • The Company had working capital of $25.0 million and 10.2 million common shares outstanding as of December 31, 2023.

COVID-19 Virus Can Persist in the Body More Than a Year after Infection

Retrieved on: 
星期二, 四月 9, 2024
Research, Infection, Harvard Medical School, HIV/AIDS, Conditional sentence, COVID, UCSF, Biomedical Research, Coronavirus, UC, Nature, University, SARS-CoV-2, MD, Volunteering, Life, Protein, Consortium, Lymph, Division, Viral, Government, Vaccine

MEDFORD, Mass., April 8, 2024 /PRNewswire/ -- Research published today in Lancet Infectious Diseases and supported by PolyBio Research Foundation provides the strongest evidence yet that the COVID virus can persist for months or years after infection. The findings, published by a UC San Francisco/Harvard Medical School team, found that proteins created by the virus were still present for up to 14 months in a quarter of people tested. This demonstrates SARS-CoV-2 viral persistence as an urgent area of research underlying a breadth of chronic disease after COVID. 

Key Points: 
  • "The fact that every new SARS-CoV-2 infection has the potential to become chronic is perhaps the single most concerning aspect of this virus," says Dr. Amy Proal, President of PolyBio.
  • "We have compelling data that viral persistence is much more common than recognized which could have major health implications."
  • The researchers analyzed blood samples from 171 people who had been infected with the virus.
  • These findings greatly bolster evidence that the coronavirus can linger in tissue and organs, even after recovery from acute infection.

VALUE LINE, INC. ANNOUNCES THIRD QUARTER EARNINGS

Retrieved on: 
星期五, 三月 15, 2024
Employment, Coronavirus, Internet, Research, Publishing, Nature, Value Line, Federal Reserve, Collection, Marketing, Mutual fund, Government, ETF, Regulation, Corporation

New York, March 15, 2024 (GLOBE NEWSWIRE) -- Value Line, Inc., (NASDAQ: VALU) reported financial results for the third fiscal quarter ended January 31, 2024.

Key Points: 
  • New York, March 15, 2024 (GLOBE NEWSWIRE) -- Value Line, Inc., (NASDAQ: VALU) reported financial results for the third fiscal quarter ended January 31, 2024.
  • Retained earnings at January 31, 2024, were $102,292,000, an increase of 6.6% compared to retained earnings at April 30, 2023.
  • Value Line’s acclaimed research also enables the Company to provide specialized products such as Value Line Select, The Value Line Special Situations Service, Value Line Select ETFs, Value Line Select: Dividend Income & Growth, The New Value Line ETFs Service, The Value Line M&A Service, Information You Should Know Wealth Newsletter, The Value Line Climate Change Investing Service and certain Value Line copyrights, distributed under agreements including certain proprietary ranking system information and other proprietary information used in third party products.
  • In this report, “Value Line,” “we,” “us,” “our” refers to Value Line, Inc. and “the Company” refers to Value Line and its subsidiaries unless the context otherwise requires.

Perma-Fix Achieves 36% Year-Over-Year Increase in Revenue to $22.7 Million for the Fourth Quarter of 2023

Retrieved on: 
星期三, 三月 13, 2024
USGS, Vitrification, Tax, PFAS, JV, COVID-19, Research, PESI, Loss, Adjustment, DOD, EPA, Treatment, European, Economy, Investment, Ecosystem, Coronavirus, Depreciation, GAAP, United States Geological Survey, Continuing resolution, Government, DOE, ERC, Video game

Revenue from the Treatment Segment increased by approximately $1.6 million to $10.2 million in the fourth quarter of 2023 from $8.6 million for the corresponding period of 2022.

Key Points: 
  • Revenue from the Treatment Segment increased by approximately $1.6 million to $10.2 million in the fourth quarter of 2023 from $8.6 million for the corresponding period of 2022.
  • Gross profit for the fourth quarter of 2023 was $4.3 million versus $2.0 million for the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was approximately $9,000 versus operating loss of $1.7 million for the fourth quarter of 2022.
  • Revenue from the Treatment Segment increased by approximately $10.1 million to $43.5 million in 2023 from $33.4 million in 2022.